TrialJournal of gynecologic oncology2024

Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.

Kan Yonemori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.